Israel's BrainsWay Q3 revenue rises on OCD coil sales

Overview

• Israel neurostimulation device maker's Q3 revenue rose 34% year-over-year

• Operating income more than doubled, adjusted EBITDA up 92% in Q3

• Company expects full-year 2026 results at upper end or above prior guidance

Outlook

• Company expects 2026 revenue, operating income margin and adj EBITDA at upper end of guidance

• Company sees growth opportunities from reimbursement coverage, increased utilization and new treatment protocols

• Company aims to strengthen market position via partnerships and expanded clinical evidence

Result Drivers

• DEEP TMS ADOPTION - Co said revenue growth was driven by increased adoption of Deep TMS systems and recurring revenue momentum

• SYSTEM SHIPMENTS - Number of Deep TMS systems shipped rose 44% year-over-year to 130 units

• OCD COIL SALES - Sales of OCD coils rose 17% year-over-year, contributing to installed base growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Brainsway Ltd is $19.00, about 63.2% above its November 9 closing price of $11.64

Reuters Recommended Reads

• Nov 9 - Israel's Kamada Q3 revenue up 11%, raises forecast

• Nov 10 - Israel's Protalix BioTherapeutics Q3 revenue rises, driven by higher sales to Chiesi

• Nov 9 - Israel's Compugen Q3 revenue doubles on Gilead payments; loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)